RRM2 overexpression plays a key role in sunitinib resistance in patients with renal cell carcinoma and that RRM2 competes with UBE3A to prevent ANXA1 degradation. The gene discussed is RRM2; the disease is hereditary clear cell renal cell carcinoma.